Bolt Biotherapeutics Inc. (BOLT)
NASDAQ (CM) NASDAQ (CM) Primary 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bolt Biotherapeutics, Inc. ("Bolt Biotherapeutics, Inc.") (NASDAQ:BOLT) concerning possible violations of federal securities laws. Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%".
Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Willie Quinn - Incoming Chief Executive Officer Randy Schatzman - Outgoing Chief Executive Officer Edith Perez - Outgoing Chief Medical Officer Michael Alonso - Co-Founder of Bolt and Senior Vice President of Research Dawn Colburn - Senior Vice President of Clinical Development. Conference Call Participants Jeffrey La Rosa - Leerink Partners Stephen Willey - Stifel Michael Schmidt - Guggenheim Operator Good afternoon, and welcome to the Bolt Biotherapeutics Strategic Update Conference Call.
Bolt Biotherapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Bolt Biotherapeutics, Inc. (BOLT)
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bolt Biotherapeutics, Inc. ("Bolt Biotherapeutics, Inc.") (NASDAQ:BOLT) concerning possible violations of federal securities laws. Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%".
BOLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Bolt Biotherapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bolt Biotherapeutics, Inc. ("Bolt Biotherapeutics, Inc.") (NASDAQ:BOLT) concerning possible violations of federal securities laws. Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%".
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT)
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bolt Biotherapeutics, Inc. ("Bolt Biotherapeutics, Inc.") (NASDAQ:BOLT) concerning possible violations of federal securities laws. Bolt announced in a press release on May 14, 2024, that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)", Bolt's lead asset, "and reduce workforce by approximately 50%".
